Kim Sang Young, Hong Chang Ki, Kim Tae Hoon, Hong Je Beom, Park Chul Hwan, Chang Yoon Soo, Kim Hyung Jung, Ahn Chul Min, Byun Min Kwang
Division of Pulmonology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Department of Neurosurgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Yonsei Med J. 2015 Jan;56(1):103-11. doi: 10.3349/ymj.2015.56.1.103.
Patients with non-small cell lung cancer (NSCLC) and simultaneously having brain metastases at the initial diagnosis, presenting symptoms related brain metastasis, survived shorter duration and showed poor quality of life. We analyzed our experiences on surgical treatment of brain metastasis in patients with NSCLC.
We performed a single-center, retrospective review of 36 patients with NSCLC and synchronous brain metastases between April 2006 and December 2011. Patients were categorized according to the presence of neurological symptoms and having a brain surgery. As a result, 14 patients did not show neurological symptoms and 22 patients presented neurological symptoms. Symptomatic 22 patients were divided into two groups according to undergoing brain surgery (neurosurgery group; n=11, non-neurosurgery group; n=11). We analyzed overall surgery (OS), intracranial progression-free survival (PFS), and quality of life.
Survival analysis showed there was no difference between patients with neurosurgery (OS, 12.1 months) and non-neurosurgery (OS, 10.2 months; p=0.550). Likewise for intracranial PFS, there was no significant difference between patients with neurosurgery (PFS, 6.3 months) and non-neurosurgery (PFS, 5.3 months; p=0.666). Reliable neurological one month follow up by the Medical Research Council neurological function evaluation scale were performed in symptomatic 22 patients. The scale improved in eight (73%) patients in the neurosurgery group, but only in three (27%) patients in the non-neurosurgery group (p=0.0495).
Patients with NSCLC and synchronous brain metastases, presenting neurological symptoms showed no survival benefit from neurosurgical resection, although quality of life was improved due to early control of neurological symptoms.
非小细胞肺癌(NSCLC)患者在初次诊断时同时伴有脑转移,出现与脑转移相关的症状,生存期较短且生活质量较差。我们分析了NSCLC患者脑转移手术治疗的经验。
我们对2006年4月至2011年12月期间36例NSCLC合并同步脑转移的患者进行了单中心回顾性研究。根据是否存在神经症状及是否接受脑手术对患者进行分类。结果,14例患者未出现神经症状,22例患者出现神经症状。有症状的22例患者根据是否接受脑手术分为两组(神经外科手术组;n = 11,非神经外科手术组;n = 11)。我们分析了总生存期(OS)、颅内无进展生存期(PFS)和生活质量。
生存分析显示,神经外科手术患者(OS,12.1个月)和非神经外科手术患者(OS,10.2个月;p = 0.550)之间无差异。同样,颅内PFS方面,神经外科手术患者(PFS,6.3个月)和非神经外科手术患者(PFS,5.3个月;p = 0.666)之间也无显著差异。对有症状的22例患者采用医学研究委员会神经功能评估量表进行了1个月的可靠神经学随访。神经外科手术组8例(73%)患者量表评分改善,而非神经外科手术组仅3例(27%)患者改善(p = 0.0495)。
NSCLC合并同步脑转移且出现神经症状的患者,神经外科切除虽未带来生存获益,但因神经症状的早期控制改善了生活质量。